Paul Cossum

Pivotal BioSciences, Inc. operates as an early-stage company which engages in the development and commercialization of cancer therapies. Its product pipeline includes PB 101, PB 103 and PB 105. The company was founded by Alan Epstein, Francis S. Markland, Jr. and Dimitri S. Villard in 1998 and is headquartered in Los Angeles, CA.

Global BioDevelopment LLC offered formulation development, immunoassay, antibody, chromatography, efficacy testing, and toxicology services. The company was founded by Michael Lewandowski and was headquartered in Clearwater, FL.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Aronex Pharmaceuticals, Inc. develops proprietary medicines to treat cancer and infectious diseases. The company's products include Nyotran, Atragen, Annamycin, and Zintevir. It is headquartered in The Woodlands, TX.

NewBiotics, Inc. develops pharmaceutical drugs to treat cancer and infectious disease. It applies its Enzyme Catalyzed Therapeutic Activation technology to develop pharmaceuticals that transform drug resistance into therapeutic advantage. The company was founded by H. Michael Shepard and Geoffrey Myles Wahl in 1997 and is headquartered in San Diego, CA.

Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA.